| Literature DB >> 15541604 |
Gian Piero Testore1, Luca Dori, Anna Rita Buonomini, Gian Carlo Schito, Ornella Soro, Giacomo Fortina, Stefano Andreoni, Nicola Carlone, Vivian Tullio, Massimo Andreoni.
Abstract
We determined the in vitro activity of fluconazole against 1565 clinical Candida spp. isolates collected from different specimens of non-AIDS outpatients and inpatients in 3 different regions of Italy. Susceptibility testing was performed by agar disk diffusion using the NCCLS document M44-A guidelines. Candida albicans was the most frequently isolated yeast (68%) followed by C. glabrata (15%), C. tropicalis (5%), C. parapsilosis (5%), and C. krusei (5%). Other yeasts represented 4% of all isolates. Of the 1565 isolates tested, 1449 (92.6%) were susceptible (S) to fluconazole, 43 (2.7%) were susceptible dose-dependent (S-DD) and 73 (4.7%) were resistant (R). Almost all (98.2%) of the C. albicans isolates were classified as S or S-DD. Despite its widespread use, fluconazole displayed good activity against the isolates we tested, and the disk diffusion method was confirmed as a reliable approach to the evaluation of in vitro susceptibility of yeasts to this antimycotic agent.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15541604 DOI: 10.1016/j.diagmicrobio.2004.07.010
Source DB: PubMed Journal: Diagn Microbiol Infect Dis ISSN: 0732-8893 Impact factor: 2.803